Merck KGaA (ETR: MRK)
Germany
· Delayed Price · Currency is EUR | Market Cap | 69.80B |
| Revenue (ttm) | 20.87B |
| Net Income (ttm) | 2.63B |
| Shares Out | 434.78M |
| EPS (ttm) | 6.03 |
| PE Ratio | 26.63 |
| Forward PE | 17.39 |
| Dividend | 2.20 (1.37%) |
| Ex-Dividend Date | Apr 29, 2024 |
| Volume | 52,164 |
| Open | 160.30 |
| Previous Close | 160.55 |
| Day's Range | 158.70 - 160.70 |
| 52-Week Range | 134.30 - 177.00 |
| Beta | 0.71 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2024 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing a... [Read more]
Financial Performance
In 2023, Merck KGaA's revenue was 20.99 billion, a decrease of -5.57% compared to the previous year's 22.23 billion. Earnings were 2.82 billion, a decrease of -15.09%.
Financial StatementsNews
MilliporeSigma Launches Single-Use Reactor Designed to Accelerate Antibody Drug Conjugate Manufacturing
First scalable single-use mixer specifically designed for ADC manufacturing Increases efficiency by 70% compared to stainless steel or glass manufacturing methods Utilizes Ultimus® Film for superior l...
Germany’s DAX 40 has a new female CEO: Daimler Truck appoints Karin Radstrom as next head in rare move
Radstrom will become just the second female CEO of a DAX 40 firm, joining Belen Garijo, the head of pharmaceutical giant Merck KGaA.
MilliporeSigma Receives Industry First EXCiPACT Certification for Cell Culture Media Manufacturing
New Pharmaceutical Auxiliary Materials cGMP standard introduced for cell culture media manufacturing Company first in the industry to receive EXCiPACT Certification Company’s cell culture media produc...
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the first patient has been dosed in the Phase III MyClad trial (NCT064635...
Merck KGaA (MKGAF) Q2 2024 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q2 2024 Results Conference Call August 1, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Lopez - Chair of Executive Board & CEO Helene...
Merck KGaA: The Drop Makes The Upside All The Sweeter
Merck KGaA remains undervalued with strong fundamentals and diverse business portfolio in healthcare, life sciences, and electronics. The company has above-average margins compared to the broader mark...
Merck KGaA, Darmstadt, Germany, Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating ...
Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced new research from the company's diverse oncology portfolio will be presented at the 2024 American ...
Merck KGaA (MKGAF) Q1 2024 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q1 2024 Results Conference Call May 15, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Garijo - Chair & CEO Helene von Roeder - CFO Ma...
Merck KGaA's Q1 adjusted profit declines less than feared
Merck KGaA on Wednesday reported better-than-expected adjusted earnings, helped by strong demand for its pharmaceuticals and amid currency-adjusted sales growth in semiconductor materials.
We are expecting life sciences to be stronger in the second half of 2024, says Merck KGaA CEO
Belén Garijo, CEO of Merck KGaA, discusses full-year results and her outlook for the life sciences industry.
Merck KGaA (MKGAF) Q4 2023 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q4 2023 Results Conference Call March 7, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Garijo - Chair & CEO Helene von Roeder - CFO M...
Merck KGaA forecasts return to organic earnings growth in 2024
Merck KGaA predicted a return to modest operating earnings growth, when adjusted for currency headwinds, citing a gradual recovery in demand for specialty materials that are used to make biotech drugs...
'Europe is lagging behind' on innovation: Merck KGaA CEO
Belén Garijo, CEO of science and technology company Merck KGaA, discusses European regulation, growth and innovation with CNBC at Davos.
4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn't One.
Drug stocks GSK, Sanofi, Merck KGaA, and Novartis look set for a good year on strong cash flows and attractive valuations, says UBS.
Merck KGaA says MS drug fails in late-stage trials
Germany's Merck KGaA said on Tuesday the company's experimental multiple sclerosis drug evobrutinib did not meet the primary goal in highly anticipated late-stage trials.
Merck KGaA Q3 earnings down 20% on weak biotech, electronics demand
Germany's diversified group Merck KGaA reported a 20% decline in quarterly operating profit on weak demand for specialty materials that are used to make biotech drugs and semiconductors.
Merck KGaA: Company With A Potential Upside
Merck KGaA is an undervalued pharma company with a long history and strong fundamentals. The company has above-average margins and a diverse business portfolio in healthcare, life sciences, and electr...
Merck KGaA widens work on 'DNA damage' drugs in deal with China's Hengrui
Germany's Merck KGaA on Monday said it struck a collaboration deal with Chinese drugmaker Jiangsu Hengrui Pharmaceuticals to widen Merck's work in an area known as "DNA damage response" drugs.
Merck KGaA says MS drug has blockbuster potential; key data expected in December
The CEO of Germany's Merck KGaA said the company's experimental multiple sclerosis drug can be a "blockbuster", an industry term for annual sales that exceed $1 billion, even after concerns emerged th...
Merck KGaA raises prospect of return to sales growth next year
Germany's diversified group Merck KGaA has raised the prospect of returning to revenue growth next year, recovering from a slump in demand for its specialty materials to produce biotech drugs and semi...
Exscientia's stock rockets toward a record gain after AI-driven drug discovery collaboration with Germany's Merck KGaA
The U.S.-listed shares of Exscientia PLC EXAI soared 28.5% toward a record one-day gain, and enough to pace all premarket gainers on major U.S. exchanges, after the U.K.-based precision medicine compa...
Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligen...
Merck KGaA: Expect A 10% CAGR EBITDA Increase In 2024-2025
Merck KGaA reported disappointing Q2 results with a decrease in gross profit and EBIT compared to the previous year. The company remains confident in its 2025 targets despite reducing its full-year gu...
Merck KGaA (MKGAF) Q2 2023 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belén Garijo - Chief Executive Officer Helene von ...